The SARAH Study
SARAH (SorAfenib versus Radioembolisation in Advanced Hepatocellular carcinoma) is a European multi-centre prospective randomised open-label study comparing the efficacy and safety of SIR-Spheres® Y-90 resin microspheres with sorafenib.
Patients with advanced HCC (Barcelona Clinic Liver Cancer [BCLC] stage C) with or without portal vein thrombosis and no extrahepatic spread, or patients with early/intermediate HCC (BCLC stage A or B) whose disease has progressed or recurred after previous therapies; and who are ineligible for surgical resection, ablation or liver transplantation were recruited.
The primary endpoint of the SARAH study is Overall Survival. Secondary endpoints include Safety, Progression-Free Survival at 6 months, Quality of Life, and Healthcare Costs.
The study completed enrolment of >460 patients in March 2015 and results are expected by mid-2017.